Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This trial focuses on premenopausal women aged 18 to 55 with hormone receptor-positive breast cancer, either early-stage or advanced. Researchers are evaluating how well ZOLADEX 10.8 mg suppresses ovarian function by measuring luteinizing hormone LH levels. The study aims to assess the consistency and degree of ovarian suppression achieved with this treatment. Participants receive two doses of ZOLADEX 10.8 mg as subcutaneous injections, administered on Day 1 and Day 85. The trial includes two parallel groups based on breast cancer stage, with treatment effects monitored over several weeks. The study is open-label, meaning both participants and researchers know the treatment being given. Throughout the study, participants undergo regular assessments of LH, estradiol levels, and menstrual status at weeks 6, 12, 18, and 24. These evaluations help determine how effectively ovarian suppression is maintained. Safety and adherence are monitored, with the primary outcome focused on LH values below a specific threshold at week 6. The total participation lasts at least 24 weeks, with follow-up visits to track hormonal changes and menstrual status.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sacituzumab govitecan-hziy SG combined with pembrolizumab compared to treatment chosen by a physician for people with triple negative breast cancer that remains after surgery and pre-surgical treatment. This phase 3 trial focuses on participants whose cancer has not been fully eliminated by prior therapies and aims to find if the experimental combination improves invasive disease-free survival. Participants are randomly assigned to one of two groups. One group receives SG intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each cycle for up to 8 cycles. The other group receives either pembrolizumab alone or pembrolizumab plus oral capecitabine as determined before randomization, also for up to 8 cycles. Treatment continues until reaching 8 cycles, disease recurrence, unacceptable side effects, physician decision, consent withdrawal, or death. During the study, participants undergo various evaluations including monitoring for invasive disease-free survival for up to 60 months and overall survival for up to 96 months. Researchers also track recurrence-free survival, distant disease-free survival, treatment side effects, laboratory abnormalities, and quality of life changes. Safety assessments occur up to 38 months after the first dose plus 30 days. This long-term follow-up helps understand the treatments impact over several years.